March 30, 2016 — Philips Healthcare introduced the first commercially available magnetic resonance (MR)-only simulation solution indicated for prostate cancer radiation oncology treatment planning in the United States. Philips has achieved 510(k) clearance from the Food and Drug Administration (FDA) for its MRCAT (Magnetic Resonance for Calculating ATtenuation) solution as part of its Ingenia MR-RT platform.

Choosing ongoing monitoring instead of immediate curative treatment (surgery or radiotherapy) leads to a better overall quality of life for men with low-risk prostate cancer.

A promising new discovery by University of California Los Angeles (UCLA) scientists could lead to a new method of identifying cancer patients that express high levels of an enzyme and are more likely to respond to cancer treatments.

Forensic researchers have for the first time established science-based standards for identifying human remains based on X-rays of an individual's spine, upper leg or the side of the skull.

IBA (Ion Beam Applications S.A.) announced the sale of IBA Molecular (IBAM) in which IBA had a 40 percent stake, to funds advised by CapVest Partners LP (“CapVest”), has closed successfully.

The Centers for Medicare & Medicaid Services Office of Minority Health (CMS OMH) released a new interactive map to increase understanding of geographic disparities in chronic disease among Medicare beneficiaries.

Civco Medical Solutions announced that it has acquired PCI Medical, a market leader in high-level disinfection products for ultrasound transducers. The acquisition equips Civco with a portfolio of hardware and consumables for cost-effective infection control compliance in the ultrasound transducer reprocessing market.

Routine mammography, widely recommended for breast cancer screening, may also be a useful tool to identify women at risk for heart disease, according to a study scheduled for presentation at the American College of Cardiology's (ACC) 65th Annual Scientific Session.

March 28, 2016 — Magnetic resonance imaging (MRI) of the cervix is more accurate than ultrasound at predicting if some women will have a preterm birth, according to a new study from Italy appearing in the online edition of Radiology.

Based on its recent analysis of the breast density assessment solutions market, Frost & Sullivan recognizes Volpara Solutions with the 2016 Global Frost & Sullivan Award for Competitive Strategy Innovation and Leadership.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now